PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|April 19, 2016
GSK Opens New Respiratory Manufacturing Facility
Author(s)Pharmaceutical Technology Editors
The facility located in Ware, UK, will be used to manufacture GSK’s Ellipta inhaler.
Advertisement
GlaxoSmithKline (GSK) opened a £56 million (approximately $80.67 million) manufacturing facility in Ware, United Kingdom, according to an April 18, 2016
The Ware facility is the latest expansion of GSK’s Ellipta inhaler manufacturing. The company says they expect the opening of the facility to nearly double production of Ellipta inhalers to at least 37 million per year by 2017, 95% of which, the company said, will be exported.
Since 2013, over 400 roles will have been created at the manufacturing site in Ware, bringing the staff total to 1200, GSK said. This includes over 30 apprentice and 50 graduate roles.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement